Molly Lewandowski, MD
Internal Medicine · Grandview, MONPI 1689630154
Payments from drug & device makers
Across 121 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$327
- Novo Nordisk$237
- Amgen$151
- AstraZeneca$135
- Pfizer$134
- Lilly USA, LLC$103
- plus $743 from 23 others
What the payments were for
- Food & beverage$1,829100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $327 |
| Novo Nordisk | 18 | $237 |
| Amgen | 10 | $151 |
| AstraZeneca | 10 | $135 |
| Pfizer | 10 | $134 |
| Lilly USA, LLC | 7 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $86 |
| Adlon Therapeutics L.p. | 6 | $84 |
| Merck | 5 | $76 |
| Biohaven Pharmaceuticals, Inc. | 3 | $62 |
| Ironshore Pharmaceuticals Inc. | 3 | $53 |
| Shire North American Group Inc | 3 | $45 |
| Boehringer Ingelheim | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Cranial Technologies, Inc | 2 | $29 |
| GSK | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Sanofi Pasteur Inc. | 2 | $23 |
| Boston Scientific | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Intersect ENT, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| Nevro Corp. | 1 | $12 |
How this compares
$1,829 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $59,542 |
| OzempicSemaglutide | 41 | $50,724 |
| JanuviaSitagliptin Phosphate | 38 | $42,747 |
| JardianceEmpagliflozin | 26 | $29,739 |
| RybelsusSemaglutide | 13 | $21,974 |
| XareltoRivaroxaban | 18 | $17,602 |
| FarxigaDapagliflozin Propanediol | 14 | $16,627 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,382 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 31 | $8,058 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $7,743 |
| Atorvastatin Calcium | 471 | $4,354 |
| Gabapentin | 168 | $4,175 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $3,784 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $3,771 |
| Levothyroxine Sodium | 393 | $3,602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $237 | $72,69954 claims |
| PfizerEliquis, Paxlovid | $134 | $60,99760 claims |
| MerckJanuvia | $76 | $42,74738 claims |
| Boehringer IngelheimJardiance | $38 | $29,73926 claims |
| GSKTrelegy Ellipta, Arexvy, Incruse Ellipta | $27 | $27,18365 claims |
| AstraZenecaFarxiga | $135 | $16,62714 claims |
| AbbVieSynthroid | $327 | $2,59533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Grandview
- Washington MuroGrandview$27K
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.